Breakfast News: Science Strikes Back at Cancer

The European Society for Medical Oncology (ESMO) Congress is currently ongoing in Madrid. This major cancer conference, running until October 27, has featured late-breaking trials displaying strong survival gains for patients. Emerging drug types like targeted antibody drugs, T-cell engagers, and vaccines have proven more effective than conventional treatments, both alone and in combination with traditional drugs.

However, global stock markets remain under pressure. U.S. indexes, the S&P 500 and Nasdaq-100, have both seen declines of 0.47% and 0.71% respectively, marking the second consecutive week of losses. Artificial intelligence-driven spending concerns and increasing oil prices have been key drivers behind this sell-off. Meta Platforms (META), down 9.4% following earnings, led this market downturn.

Meanwhile, Brent crude oil hit a six-month high of $116.72, buoyed by Middle East tensions. Despite these market challenges, certain stocks appear to present attractive investment opportunities. TransDigm Group (TDG) is one such example. With a five-year price prediction of $1,750, the stock has dropped 10% from its March recommendation and more than 30% from its July all-time high.

Despite this, the company's sales have grown by 23% in the past quarter, and its full-year outlook remains optimistic. The market seems to underestimate the resilience of TransDigm's business, making this a potentially good time to invest.